1
|
McMillen CM, Chapman NS, Hoehl RM, Skvarca LB, Schwarz MM, Handal LS, Crowe JE, Hartman AL. A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model. Nat Commun 2023; 14:4507. [PMID: 37495594 PMCID: PMC10372071 DOI: 10.1038/s41467-023-40187-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Accepted: 07/17/2023] [Indexed: 07/28/2023] Open
Abstract
Rift Valley fever virus (RVFV) is an emerging mosquito-transmitted virus that circulates in livestock and humans in Africa and the Middle East. Outbreaks lead to high rates of miscarriages in domesticated livestock. Women are also at risk of vertical virus transmission and late-term miscarriages. MAb RVFV-268 is a highly potent recombinant neutralizing human monoclonal antibody that targets RVFV. Here we show that mAb RVFV-268 reduces viral replication in rat placenta explant cultures and prevents vertical transmission in a rat model of congenital RVF. Passive transfer of mAb RVFV-268 from mother to fetus occurs as early as 6 h after administration and persists through 24 h. Administering mAb RVFV-268 2 h prior to RVFV challenge or 24 h post-challenge protects the dams and offspring from RVFV infection. These findings support mAb RVFV-268 as a pre- and post-infection treatment to subvert RVFV infection and vertical transmission, thus protecting the mother and offspring.
Collapse
Affiliation(s)
- Cynthia M McMillen
- University of Pittsburgh, Center for Vaccine Research, Pittsburgh, PA, USA
- University of Pittsburgh, Department of Infectious Diseases and Microbiology, School of Public Health, Pittsburgh, PA, USA
| | - Nathaniel S Chapman
- Vanderbilt University Medical Center, Department of Pathology, Microbiology and Immunology, Nashville, TN, USA
| | - Ryan M Hoehl
- University of Pittsburgh, Center for Vaccine Research, Pittsburgh, PA, USA
| | - Lauren B Skvarca
- University of Pittsburgh Medical Center, Magee-Womens Hospital, Department of Pathology, Pittsburgh, PA, USA
| | - Madeline M Schwarz
- University of Pittsburgh, Center for Vaccine Research, Pittsburgh, PA, USA
- University of Pittsburgh, Department of Infectious Diseases and Microbiology, School of Public Health, Pittsburgh, PA, USA
| | - Laura S Handal
- Vanderbilt University Medical Center, Vanderbilt Vaccine Center, Nashville, TN, USA
| | - James E Crowe
- Vanderbilt University Medical Center, Department of Pathology, Microbiology and Immunology, Nashville, TN, USA.
- Vanderbilt University Medical Center, Vanderbilt Vaccine Center, Nashville, TN, USA.
- Vanderbilt University Medical Center, Department of Pediatrics, Nashville, TN, USA.
| | - Amy L Hartman
- University of Pittsburgh, Center for Vaccine Research, Pittsburgh, PA, USA.
- University of Pittsburgh, Department of Infectious Diseases and Microbiology, School of Public Health, Pittsburgh, PA, USA.
| |
Collapse
|
2
|
Bowman CJ, Becourt-Lhote N, Boulifard V, Cordts R, Corriol-Rohou S, Enright B, Erkman L, Harris J, Hartmann A, Hilpert J, Kervyn S, Mattson B, Morford L, Muller M, Powell M, Sobol Z, Srinivasan R, Stark C, Thompson KE, Turner KJ, Barrow P. Science-Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels. Clin Pharmacol Ther 2023; 113:226-245. [PMID: 35388453 PMCID: PMC10083981 DOI: 10.1002/cpt.2602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 03/25/2022] [Indexed: 01/27/2023]
Abstract
This review presents a European Federation of Pharmaceutical Industries and Association/PreClinical Development Expert Group (EFPIA-PDEG) topic group consensus on a data-driven approach to harmonized contraception recommendations for clinical trial protocols and product labeling. There is no international agreement in pharmaceutical clinical trial protocols or product labeling on when/if female and/or male contraception is warranted and for how long after the last dose. This absence of consensus has resulted in different recommendations among regions. For most pharmaceuticals, contraception recommendations are generally based exclusively on nonclinical data and/or mechanism. For clinical trials, contraception is the default position and is maintained for women throughout clinical development, whereas appropriate information can justify removing male contraception. Conversely, contraception is only recommended in product labeling when warranted. A base case rationale is proposed for whether or not female and/or male contraception is/are warranted, using available genotoxicity and developmental toxicity data. Contraception is generally warranted for both male and female subjects treated with mutagenic pharmaceuticals. We propose as a starting point that contraception is not typically warranted when the margin is 10-fold or greater between clinical exposure at the maximum recommended human dose and exposure at the no observed adverse effect level (NOAEL) for purely aneugenic pharmaceuticals and for pharmaceuticals that induce fetal malformations or embryo-fetal lethality. Other factors are discussed, including contraception methods, pregnancy testing, drug clearance, options for managing the absence of a developmental toxicity NOAEL, drug-drug interactions, radiopharmaceuticals, and other drug modalities. Overall, we present a data-driven rationale that can serve as a basis for consistent contraception recommendations in clinical trials and in product labeling across regions.
Collapse
Affiliation(s)
- Christopher J Bowman
- Worldwide Research, Development, and Medical, Pfizer Inc, Groton, Connecticut, USA
| | | | | | - Rüdiger Cordts
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | | | - Brian Enright
- Preclinical Safety, AbbVie Inc., North Chicago, Illinois, USA
| | - Linda Erkman
- Preclinical Safety, Novartis Pharma, Basel, Switzerland
| | - Jayne Harris
- Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK
| | | | - Jan Hilpert
- Translational Medicine, Pharma Research and Early Development, Bayer AG, Berlin, Germany
| | | | | | | | | | - Marcy Powell
- GlaxoSmithKline, Research Triangle Park, North Carolina, USA
| | - Zhanna Sobol
- Merck & Co., Inc., West Point, Pennsylvania, USA
| | | | - Claudia Stark
- Preclinical Development, Pharma Research and Early Development, Bayer AG, Berlin, Germany
| | - Kary E Thompson
- Nonclinical Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania, USA
| | - Katie J Turner
- Nonclinical Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania, USA
| | - Paul Barrow
- Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| |
Collapse
|
3
|
Koya Y, Tanaka H, Yoshimi E, Takeshita N, Morita S, Morio H, Mori K, Fushiki H, Kamohara M. A novel anti-NGF PEGylated Fab' provides analgesia with lower risk of adverse effects. MAbs 2023; 15:2149055. [PMID: 36458900 PMCID: PMC9721442 DOI: 10.1080/19420862.2022.2149055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Nerve growth factor (NGF) has emerged as a key driver of pain perception in several chronic pain conditions, including osteoarthritis (OA), and plays an important role in the generation and survival of neurons. Although anti-NGF antibodies improve pain control and physical function in patients with clinical chronic pain conditions, anti-NGF IgGs are associated with safety concerns such as effects on fetal and postnatal development and the risk of rapidly progressive osteoarthritis. To overcome these drawbacks, we generated a novel anti-NGF PEGylated Fab' antibody. The anti-NGF PEGylated Fab' showed specific binding to and biological inhibitory activity against NGF, and analgesic effects in adjuvant-induced arthritis model mice in a similar manner to an anti-NGF IgG. In collagen-induced arthritis model mice, the anti-NGF PEGylated Fab' showed higher accumulation in inflamed foot pads than the anti-NGF IgG. In pregnant rats and non-human primates, the anti-NGF PEGylated Fab' was undetectable in fetuses, while the anti-NGF IgG was detected and caused abnormal postnatal development. The PEGylated Fab' and IgG also differed in their ability to form immune complexes in vitro. Additionally, while both PEGylated Fab' and IgG showed analgesic effects in sodium monoiodoacetate-induced arthritic model rats, their effects on edema were surprisingly quite different. While the anti-NGF IgG promoted edema over time, the anti-NGF PEGylated Fab' did not. The anti-NGF PEGylated Fab' (ASP6294) may thus be a potential therapeutic candidate with lower risk of adverse effects for various diseases in which NGF is involved such as OA and chronic back pain.
Collapse
Affiliation(s)
- Yukari Koya
- Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Japan,CONTACT Yukari Koya Astellas Pharma Inc, 21 Miyukigaoka, Tsukuba, Ibaraki, Japan
| | - Hirotsugu Tanaka
- Incubation Lab, Astellas Innovation Management LLC, Cambridge, MA, USA
| | - Eiji Yoshimi
- Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Japan
| | | | - Shuji Morita
- Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Japan
| | - Hiroki Morio
- Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Japan
| | - Kanako Mori
- Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Japan
| | - Hiroshi Fushiki
- Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Japan
| | | |
Collapse
|
4
|
DeSesso JM. Comparative anatomy, pre- and postnatal changes during the development and maturation of the small intestine: Life-stage influences on exposure. Birth Defects Res 2022; 114:449-466. [PMID: 35451574 DOI: 10.1002/bdr2.2015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 04/04/2022] [Accepted: 04/05/2022] [Indexed: 11/08/2022]
Abstract
The gastrointestinal (GI) system absorbs nutrients and xenobiotics, excretes waste, and performs immunologic and endocrine functions. The subdivisions of the mature gut and the complexity of their corrugated, absorptive luminal surfaces differ greatly among mammals. Regardless, the embryonic gut tube in all mammalian species arises when cephalocaudal folding incorporates the roof of the yolk sac into the embryo. The gut tube quickly lengthens and bulges into the umbilical cord. Upon reentry into the abdominal cavity, the gut tube begins to differentiate-a process that continues until well into the lactation period. Differentiation of the small intestine involves (1) increasing the absorptive surface area of the lumen; (2) establishing mechanisms to control the pH of luminal contents; (3) forming a hierarchical vascular system for distribution of absorbed nutrients; (4) developing a complex enteric nervous system to control motility; (5) providing a system for replenishment of cells; and (6) contributing to the immunity of the organism. Because the length of gestation varies among species typically used in safety tests and is much shorter than human gestation, the state of GI maturation at the time of parturition differs significantly. Differences in GI maturation can contribute to species differences in the rate and extent of absorption; these differences must be considered when designing and interpreting pharmacological/toxicological studies and extrapolating safety test results to humans.
Collapse
Affiliation(s)
- John M DeSesso
- Health Sciences Center, Exponent, Inc, Alexandria, Virginia, USA.,Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, District of Columbia, USA
| |
Collapse
|
5
|
Catlin NR, Cappon GD, Engel S, Rohde C, Nowland WS, Buitrago S, Scully I, Anderson AS, Bowman CJ. Maternal immunization with Group B Streptococcus six-valent polysaccharide conjugate vaccine supported by lack of toxicity in rat and rabbit fertility and developmental toxicity studies. Birth Defects Res 2021; 113:1343-1356. [PMID: 34516044 DOI: 10.1002/bdr2.1953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Revised: 08/19/2021] [Accepted: 08/31/2021] [Indexed: 11/09/2022]
Abstract
A maternal Group B Streptococcus (GBS) six-valent polysaccharide conjugate vaccine (GBS6) is being developed to protect neonates and infants up to 3 months of age through passive transfer of antibodies from the mother to the infant. Fertility and developmental toxicity studies were conducted in female Sprague Dawley rats and New Zealand White rabbits with GBS6 (20 μg capsular polysaccharide/serotype formulated with or without AlPO4 , the highest clinical dose). Females were administered the full human dose of the GBS6 formulation intramuscularly twice prior to mating and twice during gestation, to ensure that high antibody levels were maintained throughout gestation and lactation. Approximately, half of the rats and rabbits were evaluated at the end of gestation, and the remainder were evaluated at the end of lactation. Maternal blood for GBS6 serology, to measure antibody titers to the GBS6 antigens, was collected prior to the first dose, prior to mating, and at each necropsy. Blood for serology was also collected from offspring at the end of gestation and lactation. In both species, there was no evidence of vaccine-related effects on fertility, embryo-fetal development, or postnatal development of the offspring, supporting regulatory guidance that single-species evaluation would have been sufficient. Functional serum antibodies to all six serotypes in the vaccine were confirmed in maternal animals and functional serum antibodies to one or more of the six serotypes was also confirmed in some rat offspring and most of the rabbit offspring. The results of these studies supported the safety of GBS6 vaccine administration to pregnant women.
Collapse
Affiliation(s)
- Natasha R Catlin
- Drug Safety Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Gregg D Cappon
- Drug Safety Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Scott Engel
- Drug Safety Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Cynthia Rohde
- Drug Safety Research and Development, Pfizer Worldwide Research and Development, Pearl River, New York, USA
| | - William S Nowland
- Drug Safety Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Sandra Buitrago
- Vaccine Research and Development, Pfizer Worldwide Research and Development, Pearl River, New York, USA
| | - Ingrid Scully
- Vaccine Research and Development, Pfizer Worldwide Research and Development, Pearl River, New York, USA
| | - Annaliesa S Anderson
- Vaccine Research and Development, Pfizer Worldwide Research and Development, Pearl River, New York, USA
| | - Christopher J Bowman
- Drug Safety Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| |
Collapse
|
6
|
Schmidt A, Schmidt A, Markert UR. The road (not) taken - Placental transfer and interspecies differences. Placenta 2021; 115:70-77. [PMID: 34562829 DOI: 10.1016/j.placenta.2021.09.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 07/08/2021] [Accepted: 09/13/2021] [Indexed: 12/31/2022]
Abstract
Species differences are among the main reasons for the high failure rate of preclinical studies. A better awareness and understanding of these differences might help to improve the outcome of preclinical research. In reproduction, the placenta is the central organ regulating fetal exposure to a substance circulating in the maternal organism. Exact information about placental transfer can help to better estimate the toxic potential of a substance. From an evolutionary point of view, the chorioallantoic placenta is the organ with the highest anatomical diversity among species. Moreover, frequently used animal models in reproduction belong to rodents and lagomorphs, two groups that are characterized by the generation of an additional type of placenta, which is crucial for fetal development, but absent from humans: the inverted yolk sac placenta. Taken together, the translatability of placental transfer studies from laboratory animals to humans is challenging, which is supported by the fact that numerous species-dependent toxic effects are described in literature. Thus, reliable human-relevant data are frequently lacking and the toxic potential of chemicals and pharmaceuticals for humans can hardly be estimated, often resulting in recommendations that medical treatments or exposure to chemicals should be avoided for safety reasons. Although species differences of placental anatomy have been described frequently and the need for human-relevant research models has been emphasized, analyses of substances with species-dependent placental transfer have been performed only sporadically. Here, we present examples for species-specific placental transfer, including that of nanoparticles and pharmaceuticals, and discuss potential underlying mechanisms. With respect to the COVID 19-pandemic it might be of interest that some antiviral drugs are reported to feature species-specific placental transfer. Further, differences in placental structure and antibody transfer may affect placental transfer of ZIKA virus.
Collapse
Affiliation(s)
- André Schmidt
- Placenta Lab, Department of Obstetrics, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
| | - Astrid Schmidt
- Placenta Lab, Department of Obstetrics, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany
| | - Udo R Markert
- Placenta Lab, Department of Obstetrics, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany
| |
Collapse
|
7
|
Ventrella D, Ashkenazi N, Elmi A, Allegaert K, Aniballi C, DeLise A, Devine PJ, Smits A, Steiner L, Forni M, Bouisset-Leonard M, Bacci ML. Animal Models for In Vivo Lactation Studies: Anatomy, Physiology and Milk Compositions in the Most Used Non-Clinical Species: A Contribution from the ConcePTION Project. Animals (Basel) 2021; 11:ani11030714. [PMID: 33808012 PMCID: PMC7998628 DOI: 10.3390/ani11030714] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 03/01/2021] [Accepted: 03/02/2021] [Indexed: 12/31/2022] Open
Abstract
Simple Summary Nowadays, the importance of breastfeeding has been very well recognized not only by the scientific world but also by public opinion. Such awareness has nonetheless put a lot of pressure on women under chronic pharmacological medication, or that simply need to alleviate common post-partum health issues, due to the lack of scientific data regarding the potential transfer to the offspring during lactation. In such a scenario, the ConcePTION project aims at creating a trusted ecosystem that can efficiently generate and disseminate reliable evidence-based information regarding the effects of medications used during pregnancy and breastfeeding to women and their healthcare providers. Due to the need for a reliable animal species to obtain scientific data, the present review summarizes the main features contributing to the lactation process in the most commonly used laboratory animal species. Abstract The present review aims to summarize the main features of mammary gland anatomy, and the physiology of lactation and colostrum/milk in the most commonly used animal species for regulatory toxicity. The final goal is the selection of a preferred animal species to be enrolled in studies investigating the potential transfer of drugs and exogenous molecules through milk, within the Innovative Medicines Initiative (IMI) funded project ConcePTION. Reference data regarding humans were also collected and analyzed in order to highlight critical similarities and differences with the studied species. Additional practical considerations were also taken into account, such as ethical consideration regarding the chosen species which affects the group size, financial implications and technical feasibility of lactation trials (e.g., ease of sampling, volume of sampling, husbandry requirements and scientific recognition). In conclusion, the present analysis of the literature confirms the complexity of the decisional process behind the choice of an animal model for in vivo trials. For some of the evaluated species, data were either poor or missing, highlighting the necessity to generate more physiological background studies for species that are routinely used in laboratory settings. Overall, when taking into consideration ethical factors, feasible group size, milk volume and ease of milk collection, and physiological similarities with humans, minipigs seem to represent the most appropriate choice.
Collapse
Affiliation(s)
- Domenico Ventrella
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
| | - Nurit Ashkenazi
- Global Research and Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel; (N.A.); (L.S.)
| | - Alberto Elmi
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
- Correspondence: ; Tel.: +39-051-2097923
| | - Karel Allegaert
- Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium; (K.A.); (A.S.)
- Department of Clinical Pharmacology and Pharmacotherapy, KU Leuven, 3000 Leuven, Belgium
- Department of Hospital Pharmacy, Erasmus MC, 3015 GD Rotterdam, The Netherlands
| | - Camilla Aniballi
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
| | - Anthony DeLise
- Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, East Hanover, NJ 07936, USA;
| | - Patrick John Devine
- Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA;
| | - Anne Smits
- Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium; (K.A.); (A.S.)
- Neonatal Intensive Care Unit, University Hospital Leuven, 3000 Leuven, Belgium
| | - Lilach Steiner
- Global Research and Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel; (N.A.); (L.S.)
| | - Monica Forni
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
| | | | - Maria Laura Bacci
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
| |
Collapse
|
8
|
Grossmann H, Weinbauer GF, Baker A, Fuchs A, Luetjens CM. Enhanced normograms and pregnancy outcome analysis in nonhuman primate developmental toxicity studies. Reprod Toxicol 2020; 95:29-36. [PMID: 32413491 DOI: 10.1016/j.reprotox.2020.04.074] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 04/10/2020] [Accepted: 04/17/2020] [Indexed: 11/30/2022]
Abstract
The incidence of spontaneous pregnancy/infant losses is highly variable in long-tailed macaques (cynomolgus monkey), making it potentially difficult to ascertain test item-related effects in developmental toxicity studies. Therefore, pregnancy normograms had been developed by Jarvis et al. [1] to aid in the distinction of normal (e.g. test facility background) versus non-normal pregnancy outcomes. These normograms were mostly derived from embryo-fetal development studies and from PPND studies with a postnatal phase limited to seven days. However, the enhanced pre- and postnatal developmental (ePPND) study paradigm has essentially replaced these former study types. This work aims at providing enhanced normograms (e-normograms) in the context of regulatory ePPND studies. Survival functions for the prenatal phase (286 control pregnancies) and the postnatal phase (222 live infants) were estimated using the Kaplan-Meier estimator. Normograms were generated from survival curves and pseudo-study simulations. Data were available from two test facilities with comparable EU-compliant animal husbandry. Pregnancy duration/outcome as well as survival functions did not differ significantly between test facilities indicating that this husbandry system yields comparable developmental observations across different test facilities, at least in this NHP species. These novel e-normograms were developed for pregnant long-tailed macaques and provide an extended postnatal period up to three months, a new concept of separate normograms for the prenatal and the postnatal period, specific information on the perinatal phase events, a prediction of expected number of live infants for group size management, and the option to evaluate effects on pregnancy duration through distinction of live births and infant losses.
Collapse
Affiliation(s)
- Heiko Grossmann
- Otto-von-Guericke-Universität, Institut für Mathematische Stochastik, Magdeburg, Germany
| | | | - Ann Baker
- Covance Laboratories Inc., Madison, USA
| | - Antje Fuchs
- Covance Preclinical Services GmbH, Kesselfeld 29, 48163 Münster, Germany
| | - C Marc Luetjens
- Covance Preclinical Services GmbH, Kesselfeld 29, 48163 Münster, Germany.
| |
Collapse
|
9
|
Catlin NR, Mitchell AZ, Potchoiba MJ, O'Hara DM, Wang M, Zhang M, Weinbauer GF, Bowman CJ. Placental transfer of 125 iodinated humanized immunoglobulin G2Δa in the cynomolgus monkey. Birth Defects Res 2019; 112:105-117. [PMID: 31746560 DOI: 10.1002/bdr2.1615] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 10/09/2019] [Accepted: 10/26/2019] [Indexed: 12/30/2022]
Abstract
Antibody-like biopharmaceuticals cross the placenta by utilizing existing transport pathways (e.g., FcRn receptor). There are limited data evaluating this transfer during organogenesis in any species. Understanding placental transfer of antibody-like biopharmaceuticals can help to predict risk of developmental toxicity across species, including humans. To complement previously published placental transfer data in the rat with humanized IgGΔ2 (hIgG2), the timing and magnitude of transfer in the cynomolgus monkey and embryo/fetal biodistribution of maternally administered 125 I-radiolabeled hIgG2 was quantified on gestation days (GD) 35, 40, 50, 70, and 140 using gamma counting and whole body autoradiography 24 hr following intravenous injection. Chorioallantoic placental tissues were collected at all time points for Western Blot analysis with anti-FcRn antibody. Maternally administered 125 I-hIgG2 was found in embryo/fetal tissues at all time points, including organogenesis. Embryo/fetal plasma 125 I-hIgG2 concentration increased during gestation, but only slightly up to GD 70 in embryo/fetal tissues, with hIgG2 tissue concentrations generally similar between GD70 and 140. The embryo/fetal:maternal 125 I-hIgG2 plasma concentration ratio was approximately 2.3 fold higher on GD 140, in comparison to ratios on GD 40. Importantly, placental FcRn protein expression was confirmed at all timepoints. These data demonstrate placental transfer of hIgG2 in a nonhuman primate model, and at levels comparable to the rat model, raising the potential for adverse developmental outcomes by direct antibody binding to biological targets.
Collapse
|
10
|
Prell RA, Dybdal N, Arima A, Chihaya Y, Nijem I, Halpern W. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci 2019; 165:186-197. [PMID: 29893934 DOI: 10.1093/toxsci/kfy141] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Onartuzumab is an engineered single arm, monovalent monoclonal antibody that targets the MET receptor and prevents hepatocyte growth factor (HGF) signaling. Knockout mice have clearly demonstrated that HGF/MET signaling is developmentally critical. A pre- and postnatal development study (enhanced design) was conducted in cynomolgus monkeys to evaluate the potential developmental consequences following onartuzumab administration. Control or onartuzumab, at loading/maintenance doses of 75/50 mg/kg (low) or 100/100 mg/kg (high), was administered intravenously once weekly to 12 confirmed pregnant female cynomolgus monkeys per group from gestation day (GD) 20 through GD 174. Onartuzumab administration resulted in decreased gestation length, decreased birth weight, and increased fetal and perinatal mortality. A GD147 C-section was conducted for a subset of Control and High Dose monkeys, and identified placental infarcts with hemorrhage in the chorionic plate, chorionic villus and/or decidual plate. These findings were limited to placentas from onartuzumab-treated animals. In addition, decreased cellularity of the hepatocytes with dilated hepatic sinusoids was inconsistently observed in the liver of a few fetal or infant monkeys that died in the perinatal period. Surviving offspring had some evidence of developmental delay compared with controls, but no overt teratogenicity. Overall, effects on the perinatal fetuses were consistent with those reported in knockout mice, but not as severe. Onartuzumab concentrations were low or below the level of detection in most offspring, with cord blood concentrations only 1%-2% of maternal levels on GD 147. Malperfusion secondary to onartuzumab-induced placental injury could explain the adverse pregnancy outcomes, fetal growth restriction and relatively low fetal exposures.
Collapse
Affiliation(s)
- Rodney A Prell
- Department of Safety Assessment, Genentech, South San Francisco, California 94080
| | - Noel Dybdal
- Department of Safety Assessment, Genentech, South San Francisco, California 94080
| | - Akihiro Arima
- Shin Nippon Biomedical Laboratories, Ltd, Kagoshima 891-1394, Japan
| | - Yutaka Chihaya
- Shin Nippon Biomedical Laboratories, Ltd., Atsubetsu-ku, Sapporo, Hokkaido 004-0071, Japan
| | - Ihsan Nijem
- Bioanalytical Sciences/Assay Development and Technology, Genentech, South San Francisco, California 94080
| | - Wendy Halpern
- Department of Safety Assessment, Genentech, South San Francisco, California 94080
| |
Collapse
|
11
|
Chen CM, Hwang J, Chou HC. Maternal Tn Immunization Attenuates Hyperoxia-Induced Lung Injury in Neonatal Rats Through Suppression of Oxidative Stress and Inflammation. Front Immunol 2019; 10:681. [PMID: 31019509 PMCID: PMC6458300 DOI: 10.3389/fimmu.2019.00681] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Accepted: 03/12/2019] [Indexed: 11/13/2022] Open
Abstract
Hyperoxia therapy is often required to treat newborns with respiratory disorders. Prolonged hyperoxia exposure increases oxidative stress and arrests alveolar development in newborn rats. Tn antigen is N-acetylgalactosamine residue that is one of the most remarkable tumor-associated carbohydrate antigens. Tn immunization increases the serum anti-Tn antibody titers and attenuates hyperoxia-induced lung injury in adult mice. We hypothesized that maternal Tn immunizations would attenuate hyperoxia-induced lung injury through the suppression of oxidative stress in neonatal rats. Female Sprague-Dawley rats (6 weeks old) were intraperitoneally immunized five times with Tn (50 μg/dose) or carrier protein at biweekly intervals on 8, 6, 4, 2, and 0 weeks before the day of delivery. The pups were reared in room air (RA) or 2 weeks of 85% O2, creating the four study groups: carrier protein + RA, Tn vaccine + RA, carrier protein + O2, and Tn vaccine + O2. The lungs were excised for oxidative stress, cytokine, vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) expression, and histological analysis on postnatal day 14. Blood was withdrawn from dams and rat pups to check anti-Tn antibody using western blot. We observed that neonatal hyperoxia exposure reduced the body weight, increased 8-hydroxy-2-deoxyguanosine (8-OHdG) expression and lung cytokine (interleukin-4), increased mean linear intercept (MLI) values, and decreased vascular density and VEGF and PDGF-B expressions. By contrast, Tn immunization increased maternal and neonatal serum anti-Tn antibody titers on postnatal day 14, reduced MLI, and increased vascular density and VEGF and PDGF-B expressions to normoxic levels. Furthermore, the alleviation of lung injury was accompanied by a reduction in lung cytokine and 8-OHdG expression. Therefore, we propose that maternal Tn immunization attenuates hyperoxia-induced lung injury in neonatal rats through the suppression of oxidative stress and inflammation.
Collapse
Affiliation(s)
- Chung-Ming Chen
- Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan.,Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Jaulang Hwang
- Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
| | - Hsiu-Chu Chou
- Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| |
Collapse
|
12
|
Neal-Kluever A, Fisher J, Grylack L, Kakiuchi-Kiyota S, Halpern W. Physiology of the Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered Medications. Drug Metab Dispos 2018; 47:296-313. [DOI: 10.1124/dmd.118.084418] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 12/14/2018] [Indexed: 12/13/2022] Open
|
13
|
Taylor FR. CGRP, Amylin, Immunology, and Headache Medicine. Headache 2018; 59:131-150. [DOI: 10.1111/head.13432] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/24/2018] [Indexed: 12/19/2022]
|
14
|
Szikora B, Hiripi L, Bender B, Kacskovics I, Iliás A. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes. PLoS One 2017; 12:e0185662. [PMID: 28957416 PMCID: PMC5619814 DOI: 10.1371/journal.pone.0185662] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 09/15/2017] [Indexed: 11/19/2022] Open
Abstract
Despite the increasing importance of rabbit as an animal model in pharmacological studies like investigating placental transfer of therapeutic IgGs, little is known about the molecular interaction of the rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG molecules. We analyzed the interactions of the rabbit and human FcRn with rabbit and human IgG isotypes using surface plasmon resonance assay. Similar to FcRn of other species, rabbit FcRn functions in pH-dependent manner, as it binds IgGs at pH 6.0, but no binding occurs at pH 7.4. We also showed that rabbit FcRn binds rabbit IgG and human IgG1 with nearly identical affinity, whereas it has stronger interactions with the other human IgG isotypes. The similar affinity of rabbit IgG and human IgG1 for rabbit FcRn was confirmed by in vitro FcRn-mediated recycling assay. These data verify that rabbit is an appropriate animal model for analyzing the pharmacokinetics of human therapeutic monoclonal antibodies.
Collapse
Affiliation(s)
- Bence Szikora
- Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary
| | - László Hiripi
- Department of Animal Biotechnology, National Agricultural Research and Innovation Centre, Gödöllő, Hungary
| | | | - Imre Kacskovics
- Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary
- ImmunoGenes-ABS Ltd, Budakeszi, Hungary
| | - Attila Iliás
- Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary
- * E-mail:
| |
Collapse
|
15
|
Katagiri R, Ishihara-Hattori K, Frings W, Amano J, Fuchs A, Chiba S. Effects of SA237, a humanized anti-interleukin-6 receptor monoclonal antibody, on pre- and postnatal development in cynomolgus monkey. Birth Defects Res 2017; 109:843-856. [DOI: 10.1002/bdr2.1036] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 03/24/2017] [Accepted: 03/24/2017] [Indexed: 12/31/2022]
Affiliation(s)
- Ryuichi Katagiri
- Research Division; Chugai Pharmaceutical Co., Ltd.; Shizuoka Japan
| | | | - Werner Frings
- Research Division; Chugai Pharmaceutical Co., Ltd.; Shizuoka Japan
| | - Jun Amano
- Research Division; Chugai Pharmaceutical Co., Ltd.; Shizuoka Japan
| | - Antje Fuchs
- Covance Preclinical Services GmbH; Muenster Germany
| | - Shuichi Chiba
- Research Division; Chugai Pharmaceutical Co., Ltd.; Shizuoka Japan
| |
Collapse
|
16
|
Bowman CJ, Chapin RE. Goldilocks’ Determination of What New In Vivo Data are “Just Right” for Different Common Drug Development Scenarios, Part 1. ACTA ACUST UNITED AC 2016; 107:185-194. [DOI: 10.1002/bdrb.21184] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 07/29/2016] [Indexed: 12/28/2022]
Affiliation(s)
| | - Robert E Chapin
- Developmental and Reproductive Toxicology CoE; Pfizer, Inc; Groton CT USA
| |
Collapse
|
17
|
Halpern WG, Ameri M, Bowman CJ, Elwell MR, Mirsky ML, Oliver J, Regan KS, Remick AK, Sutherland VL, Thompson KE, Tremblay C, Yoshida M, Tomlinson L. Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development. Toxicol Pathol 2016; 44:789-809. [PMID: 27235322 PMCID: PMC4979743 DOI: 10.1177/0192623316650052] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Standard components of nonclinical toxicity testing for novel pharmaceuticals include clinical and anatomic pathology, as well as separate evaluation of effects on reproduction and development to inform clinical development and labeling. General study designs in regulatory guidances do not specifically mandate use of pathology or reproductive end points across all study types; thus, inclusion and use of these end points are variable. The Scientific and Regulatory Policy Committee of the Society of Toxicologic Pathology (STP) formed a Working Group to assess the current guidelines and practices on the use of reproductive, anatomic pathology, and clinical pathology end points in general, reproductive, and developmental toxicology studies. The Working Group constructed a survey sent to pathologists and reproductive toxicologists, and responses from participating organizations were collected through the STP for evaluation by the Working Group. The regulatory context, relevant survey results, and collective experience of the Working Group are discussed and provide the basis of each assessment by study type. Overall, the current practice of including specific end points on a case-by-case basis is considered appropriate. Points to consider are summarized for inclusion of reproductive end points in general toxicity studies and for the informed use of pathology end points in reproductive and developmental toxicity studies.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Amera K Remick
- WIL Research, a Charles River Company, Hillsborough, North Carolina, USA
| | | | | | | | - Midori Yoshida
- Food Safety Commission of Japan, Minato-ku, Tokyo, Japan
| | | |
Collapse
|
18
|
Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G. Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates. Reprod Toxicol 2016; 63:82-95. [DOI: 10.1016/j.reprotox.2016.05.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2015] [Revised: 04/03/2016] [Accepted: 05/18/2016] [Indexed: 01/17/2023]
|
19
|
Sohn W, Lee E, Kankam MK, Egbuna O, Moffat G, Bussiere J, Padhi D, Ng E, Kumar S, Slatter JG. An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners. Br J Clin Pharmacol 2016; 81:362-9. [PMID: 26447647 PMCID: PMC4833167 DOI: 10.1111/bcp.12798] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 10/02/2015] [Accepted: 10/06/2015] [Indexed: 11/29/2022] Open
Abstract
AIMS Denosumab is a fully human monoclonal immunoglobulin G2 antibody that inhibits bone resorption and increases bone mass and strength. The present clinical study assessed serum and seminal fluid pharmacokinetics following a single denosumab dose in healthy men, and evaluated whether denosumab in seminal fluid poses any risk to a fetus in the event of unprotected sexual intercourse with a pregnant partner. METHODS An open-label, single-dose study in 12 healthy men was conducted over a 106-day period. Subjects received a single subcutaneous dose of 60-mg denosumab on day 1. Serum and seminal fluid samples were collected at specified time points to assess denosumab pharmacokinetics. Adverse events were recorded. RESULTS Denosumab was measurable at low concentrations in seminal fluid (~2% of serum concentrations). The mean [standard deviation (SD)] maximum observed drug concentration (Cmax ) was 6170 (2070) ng ml(-1) (serum) and 100 (81.9) ng ml(-1) (seminal fluid). The median time to Cmax (tmax ) was 8 days (serum) and 21 days (seminal fluid). The mean (SD) area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUClast ) was 333 000 (122 000) day•ng ml(-1) (serum) and 5220 (4880) day•ng ml(-1) (seminal fluid). The mean (SD) Cmax and AUC ratios between seminal fluid and serum were 0.0217 (0.0154) and 0.0170 (0.0148), respectively. Using conservative assumptions for ejaculate volume (6 ml), vaginal absorption (100%) and placental transfer (100%), the measured mean denosumab seminal fluid Cmax would result in fetal exposure that was more than 110 times below the preclinically derived 'no effect level' for denosumab. CONCLUSIONS These results indicate a negligible risk to a fetus exposed to denosumab via seminal fluid transfer to a pregnant partner.
Collapse
Affiliation(s)
- Winnie Sohn
- Pharmacokinetics and Drug MetabolismAmgen Inc.Thousand OaksCAUSA
| | - Edward Lee
- Early DevelopmentAmgen Inc.Thousand OaksCAUSA
| | | | - Ogo Egbuna
- Early DevelopmentAmgen Inc.Thousand OaksCAUSA
| | - Graeme Moffat
- Comparative Biology & Safety SciencesAmgen Inc.Thousand OaksCAUSA
| | - Jeanine Bussiere
- Comparative Biology & Safety SciencesAmgen Inc.Thousand OaksCAUSA
| | | | - Eric Ng
- Global Patient SafetyAmgen Inc.Thousand OaksCAUSA
| | | | | |
Collapse
|
20
|
Reprint of “Potential seminal transport of pharmaceuticals to the conceptus”. Reprod Toxicol 2016; 59:22-30. [DOI: 10.1016/j.reprotox.2016.01.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Revised: 09/21/2015] [Accepted: 10/26/2015] [Indexed: 11/19/2022]
|
21
|
Scialli AR, Bailey G, Beyer BK, Bøgh IB, Breslin WJ, Chen CL, DeLise AM, Hui JY, Moffat GJ, Stewart J, Thompson KE. Potential seminal transport of pharmaceuticals to the conceptus. Reprod Toxicol 2015; 58:213-21. [DOI: 10.1016/j.reprotox.2015.10.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Revised: 09/21/2015] [Accepted: 10/26/2015] [Indexed: 11/15/2022]
|
22
|
Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol 2015; 73:562-70. [PMID: 26382609 DOI: 10.1016/j.yrtph.2015.08.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2015] [Revised: 08/11/2015] [Accepted: 08/31/2015] [Indexed: 12/15/2022]
Abstract
Bococizumab is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of hyperlipidemia. The evaluation of potential effects on embryo-fetal development was conducted in the rat. In a pharmacokinetic/pharmacodynamic study bococizumab was administered intravenously to pregnant Sprague-Dawley (SD) rats (n = 8/group) at 0, 10, 30, and 100 mg/kg during organogenesis. Maternal and fetal bococizumab, total cholesterol and HDL concentrations were determined. Bococizumab was well tolerated and there were no effects on ovarian or uterine parameters. Maternal and fetal bococizumab exposure increased with increasing dose, with a corresponding dose-dependent decrease in fetal cholesterol levels. Maternal cholesterol levels were decreased significantly, with reductions that were of a similar magnitude regardless of dose. In the definitive embryo-fetal development study bococizumab was administered to pregnant SD rats (n = 20/group) at 0, 10, 30, and 100 mg/kg and no adverse maternal or developmental effects were observed up to 100 mg/kg. These studies have provided an appropriate and relevant safety assessment of bococizumab in pregnant rats to inform human risk assessment, demonstrating no adverse effects on embryo-fetal development at magnitudes greater than anticipated clinical exposure and in the presence of maximal reductions in maternal cholesterol and dose-dependent reductions in fetal cholesterol.
Collapse
|
23
|
Butt M, Evans M, Bowman CJ, Cummings T, Oneda S, Shelton D, Zorbas M. Morphologic, stereologic, and morphometric evaluation of the nervous system in young cynomolgus monkeys (Macaca fascicularis) following maternal administration of tanezumab, a monoclonal antibody to nerve growth factor. Toxicol Sci 2014; 142:463-76. [PMID: 25326242 DOI: 10.1093/toxsci/kfu192] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Tanezumab, an antibody to nerve growth factor, was administered to pregnant cynomolgus monkeys at 0, 0.5, 4, and 30 mg/kg weekly, beginning gestation day (GD) 20 through parturition (∼GD165). Maternal tanezumab administration appeared to increase stillbirths and infant mortality, but no consistent pattern of gross and/or microscopic change was detected to explain the mortality. Offspring exposed in utero were evaluated at 12 months of age using light microscopy (all tissues), stereology (basal forebrain cholinergic and dorsal root ganglia neurons), and morphometry (sural nerve). Light microscopy revealed decreased number of neurons in sympathetic ganglia (superior mesenteric, cervicothoracic, and ganglia in the thoracic sympathetic trunk). Stereologic assessment indicated an overall decrease in dorsal root ganglion (thoracic) volume and number of neurons in animals exposed to tanezumab 4 mg/kg (n = 9) and 30 mg/kg (n = 1). At all tanezumab doses, the sural nerve was small due to decreases in myelinated and unmyelinated axons. Existing axons/myelin sheaths appeared normal when viewed with light and transmission electron microscopy. There was no indication of tanezumab-related, active neuron/nerve fiber degeneration/necrosis in any tissue, indicating decreased sensory/sympathetic neurons and axonal changes were due to hypoplasia or atrophy. These changes in the sensory and sympathetic portions of the peripheral nervous system suggest some degree of developmental neurotoxicity, although what effect, if any, the changes had on normal function and survival was not apparent. Overall, these changes were consistent with published data from rodent studies.
Collapse
Affiliation(s)
- Mark Butt
- *Tox Path Specialists, LLC, Frederick, Maryland 21701, Pfizer Inc., San Diego, California 92121, Pfizer Inc, Groton, Connecticut 06340, SNBL USA, Ltd., Everett, Washington 98203, and Pfizer Inc, South San Francisco, California 94080
| | - Mark Evans
- *Tox Path Specialists, LLC, Frederick, Maryland 21701, Pfizer Inc., San Diego, California 92121, Pfizer Inc, Groton, Connecticut 06340, SNBL USA, Ltd., Everett, Washington 98203, and Pfizer Inc, South San Francisco, California 94080
| | - Christopher J Bowman
- *Tox Path Specialists, LLC, Frederick, Maryland 21701, Pfizer Inc., San Diego, California 92121, Pfizer Inc, Groton, Connecticut 06340, SNBL USA, Ltd., Everett, Washington 98203, and Pfizer Inc, South San Francisco, California 94080
| | - Thomas Cummings
- *Tox Path Specialists, LLC, Frederick, Maryland 21701, Pfizer Inc., San Diego, California 92121, Pfizer Inc, Groton, Connecticut 06340, SNBL USA, Ltd., Everett, Washington 98203, and Pfizer Inc, South San Francisco, California 94080
| | - Satoru Oneda
- *Tox Path Specialists, LLC, Frederick, Maryland 21701, Pfizer Inc., San Diego, California 92121, Pfizer Inc, Groton, Connecticut 06340, SNBL USA, Ltd., Everett, Washington 98203, and Pfizer Inc, South San Francisco, California 94080
| | - David Shelton
- *Tox Path Specialists, LLC, Frederick, Maryland 21701, Pfizer Inc., San Diego, California 92121, Pfizer Inc, Groton, Connecticut 06340, SNBL USA, Ltd., Everett, Washington 98203, and Pfizer Inc, South San Francisco, California 94080
| | - Mark Zorbas
- *Tox Path Specialists, LLC, Frederick, Maryland 21701, Pfizer Inc., San Diego, California 92121, Pfizer Inc, Groton, Connecticut 06340, SNBL USA, Ltd., Everett, Washington 98203, and Pfizer Inc, South San Francisco, California 94080
| |
Collapse
|
24
|
Bowman CJ, Evans M, Cummings T, Oneda S, Butt M, Hurst S, Gremminger JL, Shelton D, Kamperschroer C, Zorbas M. Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis). Reprod Toxicol 2014; 53:105-18. [PMID: 25461901 DOI: 10.1016/j.reprotox.2014.10.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Revised: 09/11/2014] [Accepted: 10/05/2014] [Indexed: 01/03/2023]
Abstract
Two intravenous studies with tanezumab, an anti-nerve growth factor monoclonal antibody, were conducted in pregnant cynomolgus monkeys to assess potential effects on pregnancy and pre- and postnatal development. Study 1 evaluated infants up to 12 months of age following weekly maternal dosing (0, 0.5, 4 or 30 mg/kg; 18 per group) from gestation day (GD) 20 through parturition. Study 2 evaluated infants 2 months postnatally following weekly maternal dosing (0, 0.5 or 30 mg/kg; 20-21 per group) from GD 20 through 48. In the absence of maternal toxicity, tanezumab increased stillbirth and post-birth infant mortality/morbidity, decreased infant growth and resulted in microscopic changes in the peripheral sympathetic and sensory nervous system of the infants at all doses. Decreased primary antibody responses and increased incidences in skin changes in infants were also observed. The no-observed-adverse-effect-level for maternal toxicity was 30 mg/kg and <0.5 mg/kg for developmental toxicity.
Collapse
Affiliation(s)
| | | | | | | | - Mark Butt
- Tox Path Specialists, Frederick, MD, USA.
| | | | | | | | | | | |
Collapse
|
25
|
Moffat GJ, Davies R, Kwon G, Retter MW, Chellman GJ, Kanapuram S, Moore M, Loomis M, Wang W, Pyrah IT. Investigation of maternal and fetal exposure to an IgG2 monoclonal antibody following biweekly intravaginal administration to cynomolgus monkeys throughout pregnancy. Reprod Toxicol 2014; 48:132-7. [DOI: 10.1016/j.reprotox.2014.05.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Revised: 05/05/2014] [Accepted: 05/07/2014] [Indexed: 11/24/2022]
|